Trial Profile
A Phase I Pharmacokinetic and Randomized Phase II Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Saracatinib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 13 Feb 2018 Status changed from active, no longer recruiting to completed.
- 19 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 19 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.